Landy J and Hart AL |
Commentary: short-term efficacy of tacrolimus in steroid-refractory ulcerative colitis. |
2013 |
Aliment. Pharmacol. Ther. |
pmid:23336680
|
Hirai F et al. |
Letter: short-term efficacy of tacrolimus in steroid-refractory ulcerative colitis. |
2013 |
Aliment. Pharmacol. Ther. |
pmid:23336690
|
Schmidt KJ et al. |
Letter: short-term efficacy of tacrolimus in steroid-refractory ulcerative colitis - authors' reply. |
2013 |
Aliment. Pharmacol. Ther. |
pmid:23336691
|
Baumgart DC et al. |
Rescue therapy with tacrolimus is effective in patients with severe and refractory inflammatory bowel disease. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12755840
|
Yamamoto T et al. |
Tacrolimus vs. anti-tumour necrosis factor agents for moderately to severely active ulcerative colitis: a retrospective observational study. |
2016 |
Aliment. Pharmacol. Ther. |
pmid:26762838
|
Ierardi E et al. |
Oral tacrolimus long-term therapy in patients with Crohn's disease and steroid resistance. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11207512
|
Travis S |
Review article: saving the colon in severe colitis - the case for medical therapy. |
2006 |
Aliment. Pharmacol. Ther. |
pmid:16961749
|
Romano C et al. |
Oral tacrolimus (FK 506) in refractory paediatric ulcerative colitis. |
2010 |
Aliment. Pharmacol. Ther. |
pmid:20148798
|
McSharry K et al. |
Systematic review: the role of tacrolimus in the management of Crohn's disease. |
2011 |
Aliment. Pharmacol. Ther. |
pmid:21999607
|
Beckebaum S et al. |
Renal function and cardiovascular risk profile after conversion from ciclosporin to tacrolimus: prospective study in 80 liver transplant recipients. |
2009 |
Aliment. Pharmacol. Ther. |
pmid:19624550
|
Herrlinger KR et al. |
Infliximab as rescue medication for patients with severe ulcerative/indeterminate colitis refractory to tacrolimus. |
2010 |
Aliment. Pharmacol. Ther. |
pmid:20175769
|
Schwrer H et al. |
Pantoprazole and cyclosporine or tacrolimus. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11284790
|
Yamamoto T et al. |
Letter: which patient profile for tacrolimus in ulcerative colitis? Authors' reply. |
2016 |
Aliment. Pharmacol. Ther. |
pmid:27137731
|
Laharie D and Poullenot F |
Letter: which patient profile for tacrolimus in ulcerative colitis? |
2016 |
Aliment. Pharmacol. Ther. |
pmid:27137730
|
Lawrance IC and Copeland TS |
Rectal tacrolimus in the treatment of resistant ulcerative proctitis. |
2008 |
Aliment. Pharmacol. Ther. |
pmid:18761706
|
Liberal R et al. |
Expert clinical management of autoimmune hepatitis in the real world. |
2017 |
Aliment. Pharmacol. Ther. |
pmid:28004405
|
Segal JP et al. |
Systematic review with meta-analysis: the management of chronic refractory pouchitis with an evidence-based treatment algorithm. |
2017 |
Aliment. Pharmacol. Ther. |
pmid:28008631
|
Yamamoto T et al. |
Editorial: tacrolimus vs. anti-tumour necrosis factor agents for moderately to severely active ulcerative colitis--authors' reply. |
2016 |
Aliment. Pharmacol. Ther. |
pmid:27040167
|
Taylor KM and Sparrow MP |
Editorial: tacrolimus vs. anti-tumour necrosis factor agents for moderately to severely active ulcerative colitis. |
2016 |
Aliment. Pharmacol. Ther. |
pmid:27040166
|
Nakase H et al. |
Cytomegalovirus affects clinical outcome of infliximab in ulcerative colitis refractory to tacrolimus. |
2010 |
Aliment. Pharmacol. Ther. |
pmid:20636704
|